An investigation for investors in NASDAQ:PCRX shares over potential securities laws violations by Pacira Pharmaceuticals Inc was announced and NASDAQ:PCRX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 04/20/2015 --An investigation for investors in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) over potential violations of federal securities laws by Pacira Pharmaceuticals Inc (and certain of its directors and officers was announced.

Investors who purchased shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether certain statements by Pacira Pharmaceuticals Inc (NASDAQ:PCRX) regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) grew from $49.69 per share in late 2013 to as high as $108.26 per share in late August 2014.

On September 25, 2014, Pacira Pharmaceuticals Inc (NASDAQ: PCRX) announced that it received a Warning Letter from the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension).

On October 3, 2014, a lawsuit was filed against Pacira Pharmaceuticals Inc over alleged securities laws violations. The plaintiff claimed that between April 9, 2012 and September 24, 2014 defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that Pacira Pharmaceuticals Inc was overstating the efficacy of its EXPAREL drug, that Pacira Pharmaceuticals Inc was improperly promoting its EXPAREL drug by touting its ability to be effective for up to 72 hours, when in fact, it is only approved for 24 hours of pain relief, that Pacira Pharmaceuticals Inc improperly claimed that EXPAREL is safe for use in cholecystectomy and colectomy procedures, when in fact, approved labeling does not provide instructions for, or indicate that EXPAREL will be safe and effective for postsurgical pain, if used in surgical procedures other than hemorrhoidectomy or bunionectomy, that substantial portion of Pacira Pharmaceuticals Inc's revenues were derived from off label marketing, and that and as a result of the above, Pacira Pharmaceuticals Inc's financial statements were materially false and misleading at all relevant times.

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) declined to as low as $86.02 per share in November 2014.

On February 24, 2015, Pacira Pharmaceuticals Inc reported its 2014 financial results. Pacira Pharmaceuticals repoted that its annual Total Revenue rose from $85.55 million in 2013 to $197.67 million in 2014 and that its respective Net Loss declined from $63.91 million to $13.72 million. Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) grew to as high as $119.27 per share on February 25, 2015.

On March 2, 2015, Pacira Pharmaceuticals Inc received acomplete response letter from the FDS for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia.

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) declined on March 2, 2015, to as low as $92.30 per share.

Then on April 16, 2014, Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) announced that it received a subpoena from the U.S. Department of Justice U.S. Attorney's Office for the District of New Jersey requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension).

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) declined to as low as $80.16 per share on April 16, 2015.

Those who purchased shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com